Assessment of the Effect of Interferon-Beta1a Therapy on Thyroid and Salivary Gland Functions in Patients with Multiple Sclerosis Using Quantitative Salivary Gland Scintigraphy

Multipl Skleroz Hastalarında Interferon-Beta1a Tedavisinin Tiroid ve Tükrük Bezi Fonksiyonları Üzerindeki Etkisinin Kantitatif Tükrük Bezi Sintigrafisi ile Değerlendirilmesi

Seval Erhamamcı1, Bahriye Horasanlı2, Ayşe Aktaş1
1Başkent University Faculty of Medicine, Department of Nuclear Medicine, Ankara, Turkey
2Başkent University Faculty of Medicine, Department of Neurology, Ankara, Turkey

Abstract
Objective: Interferon-beta (IFN-β) is widely used in patients with multiple sclerosis (MS), a demyelinating disease of the central nervous system. High incidence of thyroid dysfunction has been reported after administration of IFN-β in MS patients. The aim of this study was to assess the effect of IFN-β1a therapy on simultaneous thyroid and salivary gland function in patients with MS using quantitative salivary gland scintigraphy (QSGS).

Methods: Fifteen relapsing-remitting (RR) MS patients treated with IFN-β1a and two control groups consisting of 15 untreated RRMS patients and 20 healthy age and sex-matched individuals were included in the study. The functional status of the salivary and thyroid glands was analysed with the QSGS and laboratory tests, including thyroid function and thyroid antibody. After intravenous administration of 150 MBq Tc-99m pertechnetate, dynamic study was performed for 25 minutes. Salivary gland secretion was stimulated with oral lemon juice at 15 minutes. At the end of dynamic study, a static image in the same projection was taken. Uptake ratios at 12-14 min (%UR) and stimulated excretion fraction (%EF) of each parotid and submandibular gland were calculated automatically from SGS. Thyroid uptake ratio (%TUR) of thyroid gland was calculated from the static image.

Results: All MS patients treated and untreated with IFN-β1a, and healthy individuals were euthyroid. Anti-thyroid peroxidase antibody (anti-TPO) was detected in 4 out of 15 MS patients (26.6%) treated with IFN-β1a. There was no significant differences in the %UR, %EF and %TUR values among MS patients treated and untreated with IFN-β1a, and healthy controls (p>0.05). Although the %TUR values in MS patients treated with IFN-β1a were less than those of the both control group, the difference was not statistically significant (p>0.05).

Conclusion: IFN-β1a therapy was demonstrated to have no effect on thyroid and salivary gland functions using QSGS in patients with MS. Thyroid and salivary gland functions were also found to remain unchanged in untreated MS patients.

Key words: Multiple sclerosis, thyroid diseases, salivary gland diseases, scintigraphy, interferon-beta1

Özet
Amaç: Santral sinir sisteminin demiyelinizan bir hastalığı olan multipl skleroz (MS) hastalarında interferon-beta (IFN-β) yaygın olarak kullanılır. MS hastalarında IFN-β verilmesinden sonra yüksek oranda tiroid fonksiyon bozukluğu bildirilmiştir. Bu çalışmanın amacı, MS hastalarında IFN-β1a tedavisinin tiroid ve tükrük bezi fonksiyonları üzerindeki etkisinin kantitatif olarak değerlendirilmesidir.

Yöntem: IFN-β1a ile tedavi edilen 15 relapsing-remitting (RR) MS hastası ve tedavi edilmemiş 15 RRMS hastası ile yaş, cinsiyet uyumlu 20 sağlıklı bireyden oluşan iki kontrol grubu çalışması dahi edilidir. Tükrük ve tiroid bezlerinin fonksiyonunu, KTBS ve tiroid fonksiyonu ile tiroid antikorları içeren laboratuvar testleriyle analiz edildi. %UR, %EF ve %TUR oranları TBS'den otomatik olarak hesaplanıdı. Tiroi bezinin tutulum oranı (%TUR) statik görüntülünden hesaplandı.

Address for Correspondence: Seval Erhamamcı MD, Başkent University Faculty of Medicine, Department of Nuclear Medicine, Ankara, Turkey
Phone: +90 332 257 06 06 E-mail: sevaler@yahoo.com Received: 13.11.2013 Accepted: 13.02.2014
Introduction

Interferon-beta (IFN-β) has been widely used to treat patients with relapsing-remitting (RR) multiple sclerosis (MS) (1,2). Since type I interferons (IFNs), mainly interferon-alpha (IFN-α) and IFN-β, modulate the immunoregulatory system, these cytokines may precipitate autoimmune disorders. IFN-β therapy has been associated with a relatively high risk of developing thyroid disease, as either organ dysfunction or autoimmunity (1,2,3,4,5,6,7). The incidence of thyroid dysfunction in patients treated with type I IFN is reported to be in the range of 1% to 35% in several studies (3,4). High incidence of thyroid dysfunction reaching up to 24% has also been reported in MS patients using IFN-β (2).

Sjögren syndrome (SS) has been reported during treatment with IFN-α 2b for chronic hepatitis C and IFN-β therapy for MS (8,9). Recent advances have revealed a major role for activation of the type I interferon (IFN) pathway in the pathogenesis of the salivary gland hypofunction (10,11). It is known that alterations in salivary cytokines are seen in SS and that these abnormal salivary cytokine levels may contribute to the progressive destruction of salivary gland tissue in SS (11).

Quantitative salivary gland scintigraphy (QSGS) using Tc99m-pertechnetate has been reported to be a particularly valuable tool for visual and quantitative assessment of gland function thus allowing assessment of the accumulation and the secretion of saliva (12,13,14). Salivary gland dysfunction due to various pathologies can be evaluated by this method. The main advantage of QSGS is the simultaneous evaluation of all major salivary glands and thyroid gland after a single intravenous injection, since the thyroid gland can easily be included in the imaging field of the SGS (14).

However, to the best of our knowledge, no report has discussed the scintigraphically determined function of thyroid and salivary glands in MS patients treated with IFN-β. The aim of the current study was to assess the effect of IFN-β1a therapy on thyroid and salivary gland functions in patients with RR MS using QSGS.

Materials and Methods

Study Population

A prospective, consecutive clinical trial was conducted. Fifteen MS patients (11 women, 4 men, mean age 35.1±8.3 years, age range 21-54 years) treated with IFN-β1a attending the outpatient clinic of the Department of Neurology were included in this study. All patients were affected by clinically definite MS and classified in the relapsing-remitting (RR) category according to McDonald’s revised criteria (15). All patients were clinically stable and off corticosteroid treatment for at least 6 months prior to the study. All patients were under IFN-β1a treatment for a mean of 3.50±2.28 years (range: 1-7 year with a minimum duration of 1 year). Of the 15 patients, 7 were getting a dose of 30 mcg (6 MIU) every week and 8 were getting a dose 44 mcg (12 MIU) every second day.

Two control groups consisting of untreated RR MS patients and normal healthy individuals were included in the study. The untreated MS group who refused to start IFN-β treatment consisted of 15 patients (12 women, 3 men, mean age 33.2±7.0 years, age range 22-45 years) with demographic characteristics similar to the IFN-β1a-treated patients. The normal control group consisted of 20 euthyroid healthy individuals (15 women, 5 men, mean age 32.2±8.1 years, age range 22-48 years) with normal thyroid function tests and with no evidence of salivary gland dysfunction.

All MS patients, treated and untreated with IFN-β1a, had no history of thyroid dysfunction prior to this study, and none had goiter on physical examination. This research was conducted by medically qualified personnel in strict accordance with the guidelines of the Başkent University Medical Faculty Institutional Review Board, regarding the Tenets of the Declaration of Helsinki. All patients and controls gave informed consent as approved by our institutional review board.

Salivary Gland Scintigraphy

After an overnight fast, dynamic SGS was performed with a large field of view single-headed gamma camera (ADAC, Argus, Philips) fitted with a low-energy, high-sensitivity, parallel-hole collimator with 140-keV photopeak for Tc-99m. The patients lied supine under the camera. The gamma-camera was positioned to include the head and neck region, so that the four major salivary glands and the thyroid gland was within the imaging field of view. Immediately after intravenous administration of 150 MBq Tc-99m pertechnetate, anterior sequential images of 1 min duration were acquired for up to 25 min. Dynamic images were digitally recorded in a 64x64 matrix with a 1.46 zoom. Salivary gland secretion was stimulated with 3 ml oral lemon juice (100% concentrated juice) instilled with a syringe at 15 min (13). At the end of the dynamic...
imaging, a static image of the same area was taken in the same position with 300,000 counts in 256x256 matrix and with a zoom factor of x 1.46.

**Imaging Quantitative Analysis**

All image acquisition and processings were performed by the same experienced specialist in nuclear medicine to ensure a meticulous and consistent technique. On all summation images of dynamic SGS, regions of interest (ROIs) used for quantification included one rectangular background ROI located over the brain and four irregular ROIs positioned over both parotid and submandibular glands (Figure 1). By computer assistance, time-activity curves (TAC) for the parotid and submandibular glands were generated. On the basis of these ROI counts on the TAC, the computer software calculated the following functional parameters for each salivary gland, as described previously (13): (1) uptake ratio (UR%): A measure of parenchymal function, that is the ratio of glandular Tc-99m pertechnetate activity at 12-14 minute post injection; (2) excretion fraction (EF%): A measure of secretory function, this value was calculated as the percentage of reduction in concentration after lemon juice stimulation.

To evaluate thyroid uptake, we calculated the thyroid uptake ratio (TUR) as the thyroid-to-background ratio on the anterior static image. We drew the ROI for the thyroid manually by contouring both thyroid lobes. Background ROI for thyroid gland were placed just lateral to the thyroid ROI, as previously reported (14).

**Laboratory Examinations**

Serum thyroid-stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), anti-thyroid peroxidase antibody (anti-TPO), and anti-thyroglobulin antibody (anti-TG) were measured by chemiluminescent enzyme immunoassay system (Immulite 2000 BioDPC, Los Angeles, Calif., USA).

**Statistical Analysis**

All thyroid and glandular parameters are expressed as mean value ± SD. Student t test and Mann-Whitney U test were used to analyze all mean values and to compare the three groups: healthy control individuals, untreated MS controls, and MS patients treated with IFN-β1a. Pearson test was used for correlation. All statistical analyses were performed using the statistical package for the social sciences software (SPSS, version 15.0; SPSS Inc., Chicago, IL, USA) for Windows, and a P value of less than 0.05 was considered statistically significant.

**Results**

All patients with MS who are with or without IFN-β1a therapy, and healthy individuals were euthyroid. In contrast to control patients, anti-TPO was detected in 4 out of 15 (26.6%) patients (3 women, 1 man) treated with IFN-β1a. On visual evaluation of thyroid scintigraphy, homogeneous uptake within each thyroid lobe (no cold or hot regions) was observed in all cases.

Comparison of scintigraphic parameters among the three groups are summarized in Table 1. No significant differences in the UR and EF values of bilateral parotid and submandibular glands, and TUR value of thyroid gland were found among MS patients with and without IFN-β1a therapy and healthy controls (p>0.05 for each). In addition, bilateral comparison of right -and left- sided glands in the same group revealed no statistically significant difference between right and left parotid and submandibular glands (p>0.05). Although the TUR values in MS patients treated with IFN-β1a were less than those of the both control group in this study, the difference was not statistically significant (p>0.05). We found no significant correlations between TUR and any of the salivary gland parameters.

**Discussion**

Interferon induced thyroiditis can manifest as clinical autoimmune thyroiditis, presenting with symptoms of classical Hashimoto’s thyroiditis or Graves’ disease, or as non-autoimmune thyroiditis (4). Non-autoimmune thyroiditis can manifest as destructive thyroiditis, with early thyrotoxicosis and later hypothyroidism, or as non-autoimmune hypothyroidism. It is believed that IFN induces thyroiditis by both immune stimulatory effects and by direct effects on the thyroid.
The most common form of autoimmune type IFN-induced thyroiditis is the presence of thyroid antibodies without thyroid dysfunction. The titers of thyroid autoantibodies have been reported to increase in 40% of hepatitis C patients treated with IFN-α (3,16). In particular, a high incidence of anti-TPO without evident alteration of thyroid function has been observed in MS patients (5). We found that 26.6% of MS patients treated with IFN-β1a without preexisting autoimmunity had anti-TPO, indicating that thyroid autoimmunity occurs more frequently in MS patients treated with IFN-β1a than untreated MS patients and healthy controls. The prevalence rate in our study was consistent with those of previous studies (16,17).

The measurement of thyroid Tc-99m pertechnetate uptake coupled with scintigraphic images of the gland provides valuable diagnostic information in patients with thyroid disease (18). Although thyroid scintigraphy has been widely used in MS patients with thyroid disease, thyroid uptake analyses was not performed. In this study, we calculated TUR as a quantitative parameter of the thyroid gland function, as previously described (14). Although the TUR values in MS patients treated with IFN-β1a were less than those of the both control group in this study, the difference was not statistically significant. Previous reports demonstrated that IFN-β1a is less immunogenic than IFN-β1b, probably due to its greater structural resemblance to the natural human protein (19). A limitation of our study was the absence of TUR analyses before IFN-β1a therapy. Further studies with larger patient groups may be needed to compare scintigraphic parameters before and after IFN-β1a therapy.

Interferons were also found to play a role in primary Sjögren’s syndrome, polymyositis, some forms of rheumatoid arthritis, and systemic sclerosis. Connective tissue diseases as seronegative polyarthritis and rheumatoid arthritis was observed even during early phase of treatment with IFN-β1a and IFN-β1b (20,21). The association between Sjögren’s syndrome and IFN-β has been reported (9), but the mechanism between IFN-β treatment and development of SS is unknown. A previous study has shown that type I IFNs and IL-6 can directly influence salivary gland function (10). In addition, some clinical trials with weekly intramuscular injections of α-IFN demonstrated improved salivary flow rates in SS patients (22).

There is no study in the literature that evaluated the effect of IFN-β on the salivary gland in patients with MS. In the current study, the effect of IFN-β1a therapy on salivary gland function was assessed using QSGS. Quantitative SGS has gained widespread acceptance in the evaluation of a variety of salivary gland disorders in the literature (12,13,14). On the basis of time-activity curves generated from a dynamic study, a variety of different quantitative parameters have been proposed as a sensitive measure of main salivary gland function. In our study, two parameters was used for assessing parenchymal function and saliva excretion, as published previously (13). We calculated UR and EF as parameters for quantifying accumulatory and secretory salivary gland functions. In our study, no significant differences in the UR and EF values in both parotid and submandibular glands in patients with IFN-β1a therapy was found compared to untreated patients and healthy controls. We were unable to compare our results with those of other scintigraphic studies as, to our knowledge, this study is the first one related to this topic.

A review of the literature reveals that there is only one study on the scintigraphic evaluation of salivary gland function in MS patients. Seze et al reported the prevalence of primary SS in primary progressive (PP) MS population as 16.7%, which is clearly higher than the usually accepted prevalence in the general population (23). In that study, the SGS, which is mainly based on visual analysis, was

| Parameters                  | MS patients treated with IFN-β1a (n=15) | Control group consisting of untreated MS patients (n=15) | Healthy control group (n=20) |
|-----------------------------|----------------------------------------|--------------------------------------------------------|-----------------------------|
| **Gender (Female/ Male)**   | 11/4                                   | 12/3                                                   | 15/5                        |
| **Mean age**                | 35.1±8.3                               | 33.2±7.0                                               | 32.2±8.1                    |
| **TUR**                     | 13.55±4.64                             | 16.01±3.55                                             | 16.47±3.69                  |
| **UR%**                     |                                        |                                                        |                             |
| Right parotid               | 2.55±1.93                              | 2.88±2.21                                              | 2.63±1.39                   |
| Left parotid                | 2.30±1.86                              | 2.68±2.67                                              | 2.41±1.43                   |
| Right submandibular         | 2.23±1.25                              | 2.16±1.25                                              | 2.21±1.27                   |
| Left submandibular          | 2.04±1.21                              | 2.48±1.71                                              | 2.07±1.28                   |
| **EF%**                     |                                        |                                                        |                             |
| Right parotid               | 41.00±18.12                            | 46.73±8.37                                             | 49.60±16.00                 |
| Left parotid                | 41.60±23.43                            | 43.60±12.73                                            | 51.80±12.82                 |
| Right submandibular         | 35.46±10.96                            | 39.53±10.32                                            | 39.45±11.03                 |
| Left submandibular          | 38.66±12.37                            | 41.40±9.61                                             | 41.00±10.69                 |

TUR: thyroid-uptake ratio, UR: uptake ratio, EF: excretion fraction
Statistically significant difference is not present among patients treated and untreated with IFN-β1a and healthy controls.
considered positive in 17 (28.3%) out of 60 patients. In 6 out of 10 (60%) PPMS patients with SS and 11 out of 50 (22%) patients PPMS without SS, SGS findings were suggestive of salivary gland dysfunction. However, the status of IFN therapy has not been mentioned in those patients. In relation to salivary gland function, we found no differences between MS patients without IFN-1a therapy and healthy controls in our study. Different salivary gland findings between these two studies might be related to differences in study population and methods used in evaluating SGS (24).

In conclusion, IFN-β1a therapy was demonstrated to have no effect on thyroid and salivary gland functions using QSGS in patients with MS. Thyroid and salivary gland functions was also found to remain unchanged in untreated MS patients. Future studies enrolling large numbers of patients will be required to confirm these findings. However, observation derived from the current study could be interesting for future trials aimed at detecting the effect of IFN-β therapy on thyroid or salivary gland function and encourage a multicentre prospective longitudinal study for addressing this question.

Conflicts of Interest
There are no conflicts of interest.

References
1. Rotondi M, Oliviero A, Proifice P, Mone CM, Biondi B, Del Buono A, Mazzioti G, Sinisi AM, Bellastella A, Carella C. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J Endocrinol Invest 1998;21:748-752.

2. Caraccio N, Dardano A, Manfredonia F, Manca L, Pasquali L, Judice A, Murri L, Ferrannini E, Monzani F. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005;90:4133-4137.

3. Koh L, Greenspan F, Yeo P. Interferon-induced thyroid dysfunction: three clinical presentations and review of the literature. Thyroid 1997;7:891-896.

4. Monzani F, Caraccio N, Dardano A, Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004;3:199-210.

5. Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon-beta-1b. Arch Neurol 1997;54:1169-1190.

6. Monzani F, Caraccio N, Meucci G, Lombardo F, Moscato G, Casolaro A, Ferdeghini M, Murri L, Ferrannini E. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 1999;141:325-331.

7. Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montarani E, Zaffaroni M, Betaferon Safety Trial Study Group. Thyroid function and autoimmunity during interferon-b 1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001;86:3525-3532.

8. Unoki H, Moriyama A, Tabaru A, Masumoto A, Otsuki M. Development of Sjögren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C. J Gastroenterol 1996;31:723-727.

9. De Santi L, Costantini MC, Annunziata P. Long time interval between multiple sclerosis onset and occurrence of primary Sjögren’s syndrome in a woman treated with interferon-beta. Acta Neurol Scand 2005;112:194-196.

10. Nandula SR, Dey P, Corbin KL, Nunemakers C, Baghavant H, Deshmukh US. Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling. J Oral Pathol Med 2013;42:66-72.

11. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjögren's syndrome. J Autoimmun 2010;35:225-231.

12. Vinage F, Santos MJ, Prata A, da Silva JC, Santos AI. Assessment of salivary gland function in Sjögren’s syndrome: the role of salivary gland scintigraphy. Autoimmun Rev 2009;8:672-676.

13. Bohuslavizki KH, Brenner S, Lassmann S, Tinnemeyer S, Törshoff G, Sippel C, Wolf H, Clausen M, Henze E. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. Nucl Med Commun 1996;17:681-686.

14. Günel SE, Yilmaz S, Karakolzi A, Aktas A. Quantitative and visual evaluation of salivary and thyroid glands in patients with primary Sjögren's syndrome using salivary gland scintigraphy: relationship with clinicopathological features of salivary, lacrimal and thyroid glands. Nucl Med Commun 2010;31:666-672.

15. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Weillim M, Thompson AJ, Weinsenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-846.

16. Preziosi D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno G, Meroni PL, Colombo M, Beck-Peccoz P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995;132:587-593.

17. Annunziata P, Lore' E, Venturini E, Morana P, Guarino E, Borghi S, Guazzi GC. Early synthesis and correlation of serum anti-thyroid antibodies with clinical parameters in multiple sclerosis. J Neurol Sci. 1999;168:32-36.

18. Kidokoro-Kuni Y, Emoto N, Cho K, Okawa S. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and Graves’ disease. J Nippon Med Sch. 2006;73:10-17.

19. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE 3rd, Cookfair DL, Simon JH, Jacobs LD. Incidence and significance of neutralizing antibodies to interferon-b 1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology. 1998;50:1266-1272.

20. Levesque MC, Ward FW, Jeery DR, Weinberg JB. Interferon-b 1a-induced polyarthritis in a patient with the HLA-DRB1*0404 allele. Arthritis Rheum 1999;42:560-573.

21. Alsalameh S, Manger B, Kern P, Kadlen J. New onset of rheumatoid arthritis during interferon-b 1b treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson (letter). Arthritis Rheum 1998;41:754.

22. Shiozawa S, Morimoto I, Tanaka Y, Shiozawa K. A preliminary study of the interferon-alpha treatment for xerostomy of Sjögren's syndrome. Br J Rheumatol 1993;32:52-54.

23. de Seze J, Devos D, Castelnovo G, Labaube P, Dubucquoi S, Stojkovic T, Ferrady D, Vermersch P. The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis. Error! Hyperlink reference not valid. 2001;57:1359-1363.

24. Schall GL, Anderson LG, Wolf RO, Herdt JR, Tarpley TM Jr, Cummings NA, Zeiger LS, Talal N. Xerostomia in Sjögren’s syndrome. Evaluation by sequential salivary scintigraphy. JAMA 1971;216:2109-2116.